Clinical Trials Logo

Refractory Cholangiocarcinoma clinical trials

View clinical trials related to Refractory Cholangiocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03878095 Suspended - Clinical trials for Malignant Solid Neoplasm

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Start date: January 30, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well olaparib and ceralasertib (AZD6738) work in treating patients with IDH mutant cholangiocarcinoma or solid tumors. Cancer is caused by changes (mutations) to genes that control the way cells function. Laboratory studies have shown that olaparib and AZD6738 can shrink IDH mutant tumors or stop them from growing. Olaparib and ceralasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.